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Introduction
Gastric cancer (GC) is one of the most common types of malignancy and is the third most frequent cause of cancer-related deaths worldwide. 1 Recently, several anticancer drugs and surgical techniques have been developed for the treatment of GC; however, the prognosis of patients with advanced GC remains poor.
Therefore, identification of new molecular biomarkers that are associated with diagnosis and/or prognosis is of utmost clinical importance.
Transducer-like enhancer of split 1 (TLE1) is a member of the Groucho/TLE family of transcriptional co-repressors and regulates the transcriptional activity of various genes. 2 Specifically, TLE1 suppresses E-cadherin, reducing the translation of WNT genes and inhibiting nuclear factor-kappa B regulated gene expression. 3, 4 TLE1 is also known to be involved in the regulation of neurogenesis as well as several developmental processes. 5, 6 fibrous tumors, and mesotheliomas. [11] [12] [13] TLE1 expression has also been demonstrated in various cell types of normal tissues, including basal keratinocytes and adipocytes, as well as perineural, endothelial, and mesothelial cells. [11] [12] [13] In hematological malignancies, the TLE1 gene is inactivated and acts as a tumor suppressor in myeloid leukemia by inhibiting cell proliferation and colony formation. 14, 15 Zhang et al. 16 reported a decrease in TLE1 expression in hepatocellular carcinomas compared to that in their adjacent non-cancerous tissues. This may suggest that the TLE1 gene plays an important role in liver tumor suppression. On the other hand, TLE1 has been shown to be selectively over-expressed in invasive breast tumors relative to non-invasive ductal carcinomas in situ and normal mammary epithelial tissues. 17 Yao et al. 18 suggested that TLE1 improves epithelial-to-mesenchymal transition in lung cancer cells through the suppression of E-cadherin and has the potential to regulate the aggressiveness of lung cancers.
Recent studies have demonstrated the variable functions of TLE1 in a number of malignancies. However, to our knowledge, TLE1 expression has not yet been evaluated in gastric adenocarcinomas. In the present study, we investigated TLE1 expression in surgically resected GC patients using IHC. The aim of our investigation was to examine the prognostic significance of TLE1 expression and to determine its association with clinicopathological parameters in GC patients.
Materials and Methods

Patient selection and tissue samples
We retrospectively analyzed data from 291 patients who underwent surgical resection for GC at the Soonchunhyang Uni- 
Tissue microarrays
Tissue microarrays (TMAs) were constructed by reviewing hematoxylin and eosin-stained slides and selecting one representative formalin-fixed paraffin-embedded archival block for each case. Tissue cores (2-mm thick) were extracted from individual formalin-fixed paraffin-embedded blocks (donor blocks) and rearranged into recipient paraffin blocks (TMA blocks) by using a trephine apparatus (SuperBioChips Laboratories, Seoul, Korea).
In addition, normal gastric mucosa specimens were included in 26
cases by using the same procedure. One section from the TMA block was stained with hematoxylin and eosin for tissue confirmation.
3. Immunohistochemical analysis of transducer-like enhancer of split 1 expression 
Immunohistochemical assessments
IHC staining was independently evaluated by JH Lee and KJ Kim, and in the rare instances where there was a discrepancy in their judgment, the two investigators reviewed the slides together using a multi-head microscope. Semi-quantitative IHC scores were assigned that included an assessment of both intensity and the extent of staining. The intensity of staining was scored on a scale of 0 to 3, corresponding to negative, weak, moderate, and strong positivity, respectively (Fig. 1) . 
Relationship between transducer-like enhancer of split 1 expression and clinicopathological parameters in gastric cancer
In the non-neoplastic gastric mucosa, TLE1 expression was Values are presented as number only, number (%), or mean±standard deviation. TLE1 = transducer-like enhancer of split 1; AJCC = American Joint Committee on Cancer; WD = well differentiated; MD = moderately differentiated; PD = poorly differentiated.
negative. In GC, 121 patients (41.6%) were positive for TLE1 (Table 1) . Table 2 (Fig. 2) . Additionally, male gender, lymphatic or perineural invasion, poor histologic grade, more advanced pathologic T/N stages, and more advanced AJCC stages were significantly associated with shorter DFS (P＜0.05) and OS rates (P＜0.05). In the multivariate Cox regression analysis, TLE1 expression was not significantly associated with survival (data not shown).
Discussion
The transcriptional co-repressor TLE1 does not bind directly to DNA, but instead interacts with other DNA-binding transcription factors to form large multi-protein complexes that are recruited to the target gene. 20 For example, TLE proteins are involved in the Wnt/b-catenin signaling pathway. These proteins bind to the transcription factor, lymphoid enhancer-binding factor 1 that displaces the Wnt activator, b-catenin. Consequently, there is a reduction in the translation of WNT genes. 3 Recently, several studies have demonstrated the oncogenic effect of TLE1.
TLE1 has been shown to inhibit the caspase-independent cell death pathway induced by the Bcl2-inhibitor of transcription 1 in various malignant cells. 21 Allen et al. 22 demonstrated that TLE1 positively regulates erb-B2 receptor tyrosine kinase 1 and 2 signaling and is over-expressed in a subset of human non-small cell carcinomas. TLE1 also potentiates epithelial-to-mesenchymal transition, partly through the suppression of E-cadherin, by recruiting histone deacetylase activity to the E-cadherin promoter in lung cancer cells. 18 In the present study, we investigated TLE1 expression in normal gastric mucosa and GC tissues. TLE1 was not expressed in normal gastric mucosa. However, TLE1 expression was detected in 41.6% of GC patients. These findings were similar to those reported previously in lung and breast cancers. Conversely, in hepatocellular carcinomas, TLE1 expression was shown to be reduced compared to that in adjacent non-cancerous tissues. 16 Zhang et al. 16 suggested that TLE1 expression could influence tumor suppression in hepatocarcinogenesis through the inactivation of the nuclear factor-kappa B pathway. In the present study, we concluded that TLE1 might have an oncogenic role in GC.
We also demonstrated a significant association between TLE1
expression and a number of informative prognostic clinicopatho- In conclusion, we are the first to demonstrate the presence of TLE1 expression in 41.6% of GCs and absence in normal gastric mucosa. This suggests that TLE1 has an oncogenic effect in gastric carcinogenesis. However, expression of TLE1 is significantly correlated with better prognostic factors, including early T/ N stages, early AJCC stages, and longer DFS and OS rates. This suggests that TLE1 expression is a good prognostic indicator in GCs. However, further studies are required to understand the mechanism of TLE1 when its expression appears contradictory.
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